Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Incidence of grade 3/4 adverse events in a randomized study of rituximab plus CHOP versus CHOP alone in elderly patients with diffuse, large B cell lymphoma

From: Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis

  Regimen
Adverse event CHOP Rituximab + CHOP
Any grade 3/4 adverse event (including grade 2 infections) 145 (74.0) 159 (78.7)
Infections   
   Bronchitis 16 (8.2) 22 (10.9)
   Urinary tract infection 17 (8.7) 19 (9.4)
   Pneumonia 13 (6.6) 10 (5.0)
   Febrile neutropenia 47 (24.0) 45 (22.3)
Respiratory disorders   
   Dyspnoea 6 (3.1) 16 (7.9)
   Cough 6 (3.1) 8 (4.0)
   Rhinitis 5 (2.6) 1 (0.5)
General disorders and administration site disorders   
   Pyrexia 32 (16.3) 26 (12.9)
   Fatigue 13 (6.6) 8 (4.0)
   General physical health deterioration 10 (5.1) 10 (5.0)
Gastrointestinal disorders   
   Vomiting 12 (6.1) 8 (4.0)
   Abdominal pain 7 (3.6) 12 (5.9)
  1. Values are expressed as n (%). CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone. Data from [30].